Dec 17 (Reuters) - Marker Therapeutics Inc MRKR.O:
MARKER THERAPEUTICS AWARDED $9.5 MILLION GRANT FROM THE CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (CPRIT) TO SUPPORT THE INVESTIGATION OF MT-601 IN PATIENTS WITH PANCREATIC CANCER
MARKER THERAPEUTICS: PLANS TO INVESTIGATE ITS POTENTIAL APPLICATION BEYOND LYMPHOMA IN PATIENTS WITH SOLID TUMORS
MARKER THERAPEUTICS INC: ANTICIPATES CLINICAL PROGRAM INITIATION IN 2025
Source text: ID:nGNX24rf9p
Further company coverage: MRKR.O
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。